RECURSION PHARMACEUTICALS, INC. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

RECURSION PHARMACEUTICALS, INC. reported Revenue From Contract With Customer Excluding Assessed Tax of $74.68 million for the year ending 2025.

  • RECURSION PHARMACEUTICALS, INC. showed an increase of +26.9% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
  • This data is from RECURSION PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
  • XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 7 years of available data (2019 to 2025), RECURSION PHARMACEUTICALS, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 3,120.4%.
  • Historical annual values: Fiscal year 2025: $74.68 million | Fiscal year 2024: $58.84 million | Fiscal year 2023: $44.58 million | Fiscal year 2022: $39.84 million | Fiscal year 2021: $10.18 million | Fiscal year 2020: $3.96 million | Fiscal year 2019: $2.32 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: